NRC Health (National Research Corporation) - Q1 2005 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2005. National Research Corporation (NRC Health) provides survey-based performance measurement, analysis, and educational services to the healthcare industry in the United States and Canada. The company assists healthcare organizations in complying with regulatory standards and improving business practices through performance tracking and custom research.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 |
|---|---|---|
| Revenues | $6,596,614 | $7,561,316 |
| Net Income | $748,100 | $1,175,198 |
| Operating Income | $1,237,873 | $1,895,118 |
| Operating Margin | 18.8% | 25.1% |
| Net Cash from Operating Activities | $2,431,337 | $3,728,148 |
| Cash and Cash Equivalents (End of Period) | $5,325,569 | $5,226,501 |
| Total Debt (Notes Payable) | $4,861,595 | $4,900,854 |
| Working Capital | $19,571,719 | $19,434,315 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 12.8% to $6.6 million, primarily due to volatility in timing and lower revenues from contracts with U.S. federal government agencies.
- Expense Mix: Direct expenses decreased 16.6% to $2.7 million, improving the direct expense ratio to 41.7% of revenue. However, Selling, General, and Administrative (SG&A) expenses increased 14.8% to $2.2 million due to expanded sales and marketing efforts, raising the SG&A ratio to 33.1%.
- Profitability: Net income dropped 36.3% to $748,100. The effective tax rate increased to 39.7% from 36.6% due to differences in state income taxes.
- Cash Flow: Operating cash flow decreased by $1.3 million compared to the prior year, driven by lower net income and changes in working capital accounts (specifically receivables and deferred revenue).
Outlook, Commentary, and Risks
- Dividend Initiation: The company announced and paid its first quarterly cash dividend in March 2005 ($0.08 per share, totaling $575,000). Future dividends are at the Board's discretion.
- Stock Repurchases: The company continues its stock repurchase program authorized in July 2003. As of May 6, 2005, 139,611 shares had been repurchased under this plan, with 364,889 shares remaining available for purchase.
- Accounting Changes: The company is evaluating the impact of adopting SFAS No. 123(R) regarding share-based payments, which will be effective for awards granted after June 15, 2005. This will require recognizing compensation cost based on grant-date fair value.
- Liquidity: Management expects operating cash flow to remain sufficient for working capital and capital expenditures. The company holds $15.0 million in marketable debt securities.
Investor Verification Checklist
- Verify the sustainability of revenue recovery from U.S. federal government contracts, which drove the Q1 decline.
- Monitor the impact of increased SG&A spending on future operating margins as sales efforts expand.
- Review the company's cash burn rate relative to the new quarterly dividend obligation and ongoing stock repurchases.
- Assess the potential financial impact of the upcoming adoption of SFAS No. 123(R) on reported net income.
- Confirm the timeline for recognizing the $4.4 million in deferred revenue (billings in excess of revenues earned).